Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA

NCT02769286 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Lung Neoplasms
EGFR Gene Mutations

Interventions

DRUG: Osimertinib

Sponsor

Chonnam National University Hospital